The April 2018 issue of Pharmafocus is now live!
pharmafile | March 27, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Janssen, Martin Shkreli, Right to try, atrial fibrillation, falsified medicines directive, oncology, opioids, pharma
As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce that the April 2018 issue of Pharmafocus is available to read online now.
Leading the issue is the news that the hotly-debated ‘right to try’ bill successfully passed through the US House of Representatives, ostensibly providing terminally ill patients with last resort access to potentially life-saving drugs. However, while this could be a crucial victory for patient rights, things are not as simple as they appear – you can find out the full story on pages 1 and 7.
A startling development in the ongoing US opioid crisis, new research from the Minneapolis Veterans Affairs Health Care System has found that, for all their risks, the dangerous drug class do not provide any benefits in the treatment of pain over traditional painkillers. Pharmafocus spoke to lead researcher Dr Erin Krebs to find out what this could mean for curbing the epidemic – you can read more on page 9.
Notorious “pharma bro” Martin Shkreli, who rose to infamy after hiking the price of HIV-related toxoplasmosis drug Daraprim by 5,000%, has finally seen his actions catch up with him as he is sentenced to seven years in jail for securities fraud. Justice may have been done, but the story leaves behind big questions over pricing in the industry. You can read more on page 10.
Also in the issue, we look into the impact the upcoming Falsified Medicines Directive in Europe will have on future innovation in pharmaceutical packaging and labelling, and we speak to Tony Green to discuss his atrial fibrillation diagnosis, and how AliveCor’s KardiaMobile smartphone ECG device was instrumental in securing a path to treatment.
Read the Pharmafocus April 2018 issue online now!
Matt Fellows
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
